Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Mimedx (MDXG) over the last 14 years, with Q3 2025 value amounting to $83000.0.

  • Mimedx's Gains from Investment Securities fell 2454.55% to $83000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 1290.56%. This contributed to the annual value of $2.6 million for FY2024, which is 147202.38% up from last year.
  • Latest data reveals that Mimedx reported Gains from Investment Securities of $83000.0 as of Q3 2025, which was down 2454.55% from $526000.0 recorded in Q2 2025.
  • In the past 5 years, Mimedx's Gains from Investment Securities registered a high of $3.2 million during Q1 2021, and its lowest value of -$1000.0 during Q4 2022.
  • Its 5-year average for Gains from Investment Securities is $738562.5, with a median of $160000.0 in 2021.
  • In the last 5 years, Mimedx's Gains from Investment Securities plummeted by 9966.41% in 2023 and then surged by 5370000.0% in 2024.
  • Over the past 5 years, Mimedx's Gains from Investment Securities (Quarter) stood at $188000.0 in 2021, then plummeted by 100.53% to -$1000.0 in 2022, then soared by 13300.0% to $132000.0 in 2023, then crashed by 77.27% to $30000.0 in 2024, then surged by 176.67% to $83000.0 in 2025.
  • Its Gains from Investment Securities stands at $83000.0 for Q3 2025, versus $526000.0 for Q2 2025 and $2.5 million for Q1 2025.